Market Cap | 2.98B | P/E | - | EPS this Y | -10.50% | Ern Qtrly Grth | - |
Income | -124.44M | Forward P/E | -19.11 | EPS next Y | -19.00% | 50D Avg Chg | 22.00% |
Sales | 192.85M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 32.00% |
Dividend | N/A | Price/Book | 27.64 | EPS next 5Y | - | 52W High Chg | -5.00% |
Recommedations | 3.00 | Quick Ratio | 2.39 | Shares Outstanding | 77.91M | 52W Low Chg | 101.00% |
Insider Own | 7.43% | ROA | -10.43% | Shares Float | 60.15M | Beta | 0.79 |
Inst Own | 88.54% | ROE | -95.22% | Shares Shorted/Prior | 4.77M/2.88M | Price | 38.22 |
Gross Margin | -17.92% | Profit Margin | -64.53% | Avg. Volume | 3,031,618 | Target Price | 38.25 |
Oper. Margin | -62.88% | Earnings Date | May 4 | Volume | 5,540,084 | Change | 0.00% |
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
Chardan Capital | Neutral | Dec 9, 21 |
RBC Capital | Sector Perform | Nov 19, 21 |
HC Wainwright & Co. | Neutral | Nov 18, 21 |
Goldman Sachs | Neutral | Aug 11, 21 |
Chardan Capital | Buy | Aug 10, 21 |
HC Wainwright & Co. | Buy | Aug 10, 21 |
Citigroup | Neutral | Aug 9, 21 |
RBC Capital | Outperform | Aug 6, 21 |
Goldman Sachs | Buy | Aug 6, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
FAMBROUGH DOUGLAS | Chief Executive Offi.. Chief Executive Officer | Dec 10 | Option | 3.2 | 179,865 | 575,568 | 223,029 | 12/13/21 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Jun 24 | Option | 19.85 | 18,435 | 365,935 | 18,704 | 06/24/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jun 15 | Option | 9.09 | 10,000 | 90,900 | 31,517 | 06/15/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jun 15 | Sell | 34 | 10,000 | 340,000 | 21,517 | 06/15/21 |
Ciappenelli Robert D. | Chief Commercial Off.. Chief Commercial Officer | Jun 15 | Option | 15.61 | 30,000 | 468,300 | 23,773 | 06/15/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jun 08 | Option | 9.09 | 10,000 | 90,900 | 31,517 | 06/08/21 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Jun 03 | Option | 12.93 | 4,431 | 57,293 | 4,431 | 06/03/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jun 03 | Option | 3.42 | 8,312 | 28,427 | 29,829 | 06/03/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Apr 05 | Option | 3.2 | 8,312 | 26,598 | 29,829 | 04/05/21 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Apr 05 | Option | 12.93 | 4,431 | 57,293 | 4,431 | 04/05/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jan 27 | Option | 9.09 | 16,630 | 151,167 | 43,147 | 01/27/21 |
Brown Bob D | Chief Scientific Ofr.. Chief Scientific Ofr., EVP R&D | Jan 27 | Sell | 25 | 21,630 | 540,750 | 21,517 | 01/27/21 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Jan 27 | Option | 12.93 | 4,431 | 57,293 | 6,326 | 01/27/21 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Jan 27 | Sell | 25 | 6,326 | 158,150 | 01/27/21 | |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Jan 12 | Sell | 23.99 | 3,800 | 91,162 | 33,868 | 01/12/21 |
Brown Bob D | See Remarks See Remarks | Dec 03 | Option | 3.42 | 8,185 | 27,993 | 34,702 | 12/03/20 |
Brown Bob D | See Remarks See Remarks | Dec 03 | Sell | 25.19 | 8,185 | 206,180 | 26,517 | 12/03/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Dec 03 | Option | 3.42 | 4,360 | 14,911 | 36,220 | 12/03/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Dec 03 | Sell | 25.21 | 4,360 | 109,916 | 31,860 | 12/03/20 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Nov 06 | Option | 12.93 | 30,000 | 387,900 | 30,000 | 11/06/20 |
Paglia Regina M. | Chief Human Resource.. Chief Human Resources Officer | Nov 06 | Sell | 22.75 | 30,000 | 682,500 | 11/06/20 | |
Brown Bob D | See Remarks See Remarks | Nov 03 | Option | 3.42 | 8,185 | 27,993 | 34,702 | 11/03/20 |
Brown Bob D | See Remarks See Remarks | Nov 03 | Sell | 21.03 | 8,185 | 172,131 | 26,517 | 11/03/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Nov 03 | Option | 3.42 | 4,360 | 14,911 | 36,220 | 11/03/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Nov 03 | Sell | 20.95 | 4,360 | 91,342 | 31,860 | 11/03/20 |
Brown Bob D | See Remarks See Remarks | Oct 20 | Option | 3.42 | 16,370 | 55,985 | 42,887 | 10/20/20 |
Brown Bob D | See Remarks See Remarks | Oct 20 | Sell | 21 | 16,370 | 343,770 | 26,517 | 10/20/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Oct 19 | Option | 3.42 | 8,720 | 29,822 | 30,580 | 10/19/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Oct 19 | Sell | 20.2 | 8,720 | 176,144 | 21,860 | 10/19/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Sep 04 | Sell | 26.63 | 4,360 | 116,107 | 21,860 | 09/04/20 |
Weissman James B | Chief Operating Offi.. Chief Operating Officer & EVP | Sep 04 | Option | 2.97 | 4,360 | 12,949 | 26,220 | 09/04/20 |